Investment
Features
FeesSafety
Academy
More
Pluang+

Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs Merck & Co., Inc. (MRK) Price & Performance

MONDELEZ INTERNATIONAL INC Common StockTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

MONDELEZ INTERNATIONAL INC Common Stock vs Merck & Co., Inc. — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $61.99 (market cap $78.85B), while Merck & Co., Inc. trades at $133.82 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 4.1× MONDELEZ INTERNATIONAL INC Common Stock's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays the higher dividend (3.24%). Which is the better fit depends on your goals.

MDLZMRK
Market Cap
$78.85B$321.77B
Sector
Consumer StaplesHealth
52-Week High
$64.99$131.84
52-Week Low
$51.51$77.60
Enterprise Value
$99.19B$368.53B
Dividend Yield
3.24%2.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

MONDELEZ INTERNATIONAL INC Common Stock

Mondelez International (MDLZ) trades at $61.71, up 0.28% on the day, reflecting steady momentum after a series of earnings beats. The stock exhibits a bullish technical trend, supported by strong moving averages. Fundamentally, the company reported Q2 2026 EPS of $0.73, exceeding estimates, and raised its organic sales outlook for 2026. Revenue growth is solid, though net income margin compression from 2023 peaks remains a watch point. Analyst sentiment is overwhelmingly positive, with a consensus price target of $70.50 implying significant upside.

The outlook for MDLZ is favorable, driven by pricing power, volume growth in emerging markets, and a robust brand portfolio. Key opportunities include market share gains and consistent dividend payments. Primary risks involve exposure to international economic volatility, inflationary cost pressures, and intense competition in the snack food industry. The stock presents a compelling case for growth-oriented investors seeking stability in consumer staples.

Merck & Co., Inc.

MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.

MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About MONDELEZ INTERNATIONAL INC Common Stock

Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.

Read more on MDLZ

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK